BioSpace News Archive

Fulcrum Therapeutics, Inc.® announced that the company granted non-statutory stock options to Patrick Horn, M.D., Ph.D., the company’s newly appointed chief medical officer.

IBEX Technologies Inc. (“IBEX” or the “Company”) (TSX Venture: IBT) today reported its financial results for the second quarter and the six months ended January 31, 2024.

Castle Biosciences, Inc. announced that new data highlighting the performance of its DecisionDx-Melanoma test in predicting risk of sentinel lymph node positivity in patients with CM is being presented at the Society of Surgical Oncology 2024 Annual Meeting, being held March 20-23 in Atlanta.

Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved OPSYNVI® – a single-tablet combination of macitentan, an endothelin receptor antagonist (ERA), and tadalafil, a phosphodiesterase 5 (PDE5) inhibitor – for the chronic treatment of adults with pulmonary arterial hypertension (PAH, World Health Organization [WHO] Group I) and WHO functional class (FC) II-III.

According to Vision Research Reports, the global immunotherapy drugs market size was valued at USD 239.21 billion in 2023 and it is projected to hit around USD 1,063.44 billion by 2032, growing at a CAGR of 18.03% from 2023 to 2032.

MAIA Biotechnology, Inc., a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, announced that independent director Mr. Stan V. Smith, Ph.D. made an individual purchase of 170,940 shares of the Company’s common stock as part of the Company’s recent private placement of common stock and warrants.

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today reported financial results for the three and 12 months ended December 31, 2023 and provided a business update.

Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today reported its financial results for the fiscal year ended December 31, 2023.

Savara Inc., a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the grant of inducement awards to two new employees.

Masimo, a global leader in noninvasive monitoring technologies and audio products, announced that its Board of Directors has authorized management to evaluate a proposed separation of its consumer business.